Alpha Tau Medical (DRTS) Non-Current Deferred Tax Liability (2025 - 2026)

Alpha Tau Medical (DRTS) reported Non-Current Deferred Tax Liability of $85000.0 for Q1 2026, down 12.37% sequentially from $97000.0 in Q4 2025.

Alpha Tau Medical (DRTS) Non-Current Deferred Tax Liability (2025 - 2026) Analysis & Trends

Alpha Tau Medical (DRTS) has 2 years of Non-Current Deferred Tax Liability data on file, last reported at $85000.0 in Q1 2026.

For the quarter ending Q1 2026, Non-Current Deferred Tax Liability changed N/A year-over-year to $85000.0; the trailing twelve-month figure through Mar 2026 stood at $85000.0 (changed N/A YoY), and the FY2025 full-year result was $97000.0, changed N/A from the prior year.
Non-Current Deferred Tax Liability eased to $85000.0 in Q1 2026, from $97000.0 in the prior quarter.
In the past five years, Non-Current Deferred Tax Liability ranged from a high of $160000.0 in Q2 2025 to a low of $85000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Alpha Tau Medical	1.12 Bn	1.04 Bn	-

Download Data